A specialty vaccine company based in France announced it had initiated a pivotal Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
Pre-IPO Company Launches Phase 3 COVID-19 Vaccine Study
Few SARS-CoV-2 Vaccine Breakthrough Infections Reported at SNFs
22 infections identified among 12 residents and 10 staff members at 15 skilled nursing facilities; no facility-associated secondary transmission reported
Single-Dose Ad26.COV2.S Effective Against COVID-19
Also effective against cases in South Africa, which mainly comprised infections caused by the 20H/501Y.V2 variant
Severe Maternal Morbidity, Mortality Up With COVID-19 in Pregnancy
Asymptomatic women with COVID-19 diagnosis only have increased risks for maternal morbidity and preeclampsia
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of April 19 to 23, 2021. This …
FDA Moves to Resume Use of J&J COVID Vaccine
Johnson & Johnson has agreed with the U.S. Food and Drug Administration to add a warning label to the vaccine
Pfizer and Moderna Vaccines Effective Against New NYC Variant
Studies add to growing evidence that the two vaccines protect against all coronavirus variants identified so far